{"id":"placebo-of-d723","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3770173","moleculeType":"Small molecule","molecularWeight":"440.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo formulation, D723 contains no active pharmaceutical ingredient and produces no direct molecular or therapeutic effect. It is used in phase 3 clinical trials as a control comparator to assess the efficacy and safety of the actual investigational drug against baseline/no treatment.","oneSentence":"D723 is a placebo control with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:04.199Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03583905","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-04-04","conditions":"Hypertensive Patients With Dyslipidemia","enrollment":154}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of D723","genericName":"Placebo of D723","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}